https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-healthcare-professionals-on-pfizerbiontech-covid-19-vaccine
Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine
Updated 10 December 2020
Regulation 174 Information for UK healthcare professionals
This medicinal product does not have a UK marketing authorisation but has been given
authorisation for temporary supply by the UK Department of Health and Social Care and the
Medicines & Healthcare products Regulatory Agency for active immunization to prevent
COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 16 years of age and over.
As with any new medicine in the UK, this product will be closely monitored to allow quick
identification of new safety information. Healthcare professionals are asked to report any
suspected adverse reactions. See section 4.8 for how to report adverse reactions.
Deutschland Kurier
https://www.youtube.com/watch?v=B0CBFCt3vVs
Die E-Auto-Lobby jubelt, weil die noch immer lächerlich geringen Zulassungszahlen im Herbst deutlich zugenommen haben. Die Erklärung dafür ist denkbar einfach: Wir Steuerzahler pampern den E-Auto-Irrsinn, den sich nur wenige leisten können, jetzt mit bis zu 10.000 Euro pro Neuwagenkauf. Diese exorbitante Flop-Subventionierung wird unter den großen Corona-Schuldenteppich gekehrt – nach dem Motto: Darf’s ein paar Milliarden mehr sein …
Damit der Deutschland-Kurier weiterhin augenöffnende Videos produzieren kann benötigt er IHRE spende! Vielen Dank!
Spendenkonto: https://www.deutschland-kurier.org/spenden/
https://www.mdpi.com/1660-4601/17/22/8674/htm
Abstract
We performed a retrospective analysis spanning ten years of pediatric practice focused on patients with variable vaccination born into a practice, presenting a unique opportunity to study the effects of variable vaccination on outcomes. The average total incidence of billed office visits per outcome related to the outcomes were compared across groups (Relative Incidence of Office Visit (RIOV)). RIOV is shown to be more powerful than odds ratio of diagnoses. Full cohort, cumulative incidence analyses, matched for days of care, and matched for family history analyses were conducted across quantiles of vaccine uptake. Increased office visits related to many diagnoses were robust to days-of-care-matched analyses, family history, gender block, age block, and false discovery risk. Many outcomes had high RIOV odds ratios after matching for days-of-care (e.g., anemia (6.334), asthma (3.496), allergic rhinitis (6.479), and sinusitis (3.529), all significant under the Z-test). Developmental disorders were determined to be difficult to study due to extremely low prevalence in the practice, potentially attributable to high rates of vaccine cessation upon adverse events and family history of autoimmunity. Remarkably, zero of the 561 unvaccinated patients in the study had attention deficit hyperactivity disorder (ADHD) compared to 0.063% of the (partially and fully) vaccinated. The implications of these results for the net public health effects of whole-population vaccination and with respect for informed consent on human health are compelling. Our results give agency to calls for research conducted by individuals who are independent of any funding sources related to the vaccine industry. While the low rates of developmental disorders prevented sufficiently powered hypothesis testing, it is notable that the overall rate of autism spectrum disorder (0.84%) in the cohort is half that of the US national rate (1.69%). The practice-wide rate of ADHD was roughly half of the national rate. The data indicate that unvaccinated children in the practice are not unhealthier than the vaccinated and indeed the overall results may indicate that the unvaccinated pediatric patients in this practice are healthier overall than the vaccinated.